Navigation Links
Study Probes Use of Filter Device to Stop Deadly Blood Clots
Date:3/18/2013

MONDAY, March 18 (HealthDay News) -- The use of a special filter to prevent potentially deadly blood clots from traveling to patients' lungs varies widely among hospitals, a new study finds.

A vena cava filter is placed in the inferior vena cava, the large vein in the abdomen that returns blood from the lower body to the heart. It is one of the treatments for people with blood clots that develop in the veins of the leg or pelvis (deep vein thrombosis).

These blood clots can break free and travel to the lungs, where they can cause severe complications or death. A vena cava filter, which is designed to trap these clots before they reach the lungs, may be the only treatment option for patients who can't be given blood-thinning drugs.

But one expert notes that the evidence around the effectiveness of these devices has never been clear.

"Vena cava filters were once thought to be lifesaving devices in patients [with clots] who could not tolerate the methods of blood thinners," explained Dr. Alisha Oropallo, director of wound care and hyperbarics at North Shore-LIJ Health System, Lake Success, NY.

However, "more recent data has come to light which leads physicians to question the true efficacy of vena cava filters," she said.

In the new study, researchers looked at the use of vena cava filters at 263 hospitals in California between January 2006 and December 2010. The data showed that vena cava filters were used in nearly 15 percent of more than 130,000 hospitalizations for deep vein thrombosis.

However, the frequency of vena cava filter use at the hospital varied widely, ranging from 0 percent to nearly 39 percent of deep vein thrombosis cases. Patient factors associated with the use of vena cava filters included: bleeding at the time of hospital admission; a major operation after admission for deep vein thrombosis; having advanced cancer; and being extremely ill.

Hospital characteristics associated with the use of vena cava filters included having a small number of beds and being in a rural area, according to the study published online March 18 in the journal JAMA Internal Medicine.

The findings suggest that the use of vena cava filters is largely based on a hospital's culture and practice patterns, according to Dr. Richard White, of the University of California, Davis, and colleagues.

Hospitals may be more or less reluctant to use the filters because the data on their effectiveness remains unclear, the researchers said. "The absence of reliable data indicating a clear benefit [or clear harm] associated with [vena cava filter] use likely contributes to the wide variation in use that we observed," they concluded.

Oropallo agreed. "The need for a proper randomized trial [into vena cava filter use] is necessary," she said. "Until such studies are completed, it will remain difficult for physicians to properly guide their patients to the appropriate treatment for certain circumstances."

More information

The American College of Radiology, Radiological Society of North America has more about vena cava filters.

-- Robert Preidt

SOURCES: Alisha Oropallo, MD, Director, Wound Care & Hyperbarics, North Shore-LIJ Health System, Lake Success, N.Y.; JAMA Internal Medicine, news release, March 18, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Patients Health Care Costs Unaffected by Doctors Sex: Study
2. Study confirms difference in radical prostatectomy outcomes between surgeons
3. Consumers View Foods With Green Labeling as Healthier: Study
4. Study shows rising rate of propofol abuse by health care professionals
5. UK study: Epigenetic changes play a key role in development of chemo resistance in BCa
6. New study points to the aggressive potential of small kidney tumors, advocates treatment
7. New study: Incidence and mortality of PCa after termination of PSA-based screening
8. Study shows community approach effective in fight against diabetes
9. Study: Smoking Increases HPV Risks; polyDNA Recommends Gene-Eden-VIR Against HPV
10. Omega XL Reports New Independent Study: Omega-3s Can Boost Children’s IQ
11. Childhood Depression May Be Tied to Later Heart Risk: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Probes Use of Filter Device to Stop Deadly Blood Clots
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand ... project," said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s ... within Final Cut Pro X . Simply select a ProHand generator and drag ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article ... people are unfamiliar with. The article goes on to state that individuals are now ... of these less common operations such as calf and cheek reduction. The Los Angeles ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: